Earlier this year in May, specialty pharmaceutical giant, EUSA announced a change in its top leadership spectrum. Internationally renowned business executive, Dr. Carsten Thiel was named President of the European division. It’s a recently added position and Thiel’s selection highlights the tremendous progression of his career in 27 years. He joined EUSA Pharma following tenure as the Chief Executive Officer with Abeona Therapeutics Incorporated.
He’s acquired extensive knowledge, thoroughly demonstrating unparalleled performance within various international organizations, including those with groundbreaking curative treatments in the scope of pharmaceutical oncology and rare diseases. These are areas that Carsten Thiel has been involved in since earning his doctorate from the Max Planck Institute for Biophysical Chemistry, in Göttingen, Germany. His educational pursuits include traveling to the UK from his native Germany to get his undergraduate degree at the University of Bristol.
As one would expect of a higher education graduate of the prestigious Max Planck Institute, Thiel has performed well in an array of roles. His experience in the field came while concentrating on cures for rare diseases with firms such as Alexion Pharmaceuticals, where he served as Chief Commercial Officer. Additionally, Carsten Thiel was promoted following his work with Alexion when he accepted the role of Head of Europe at Amgen. Initially, upon graduating with his Ph.D., he was employed at the branded pharmaceutical leader, Fritz Hoffmann-La Roche.
When the positions were made public, Carsten Thiel made a comment about joining EUSA Pharma, he stated that “I am honored to lead the expansion.” This was in reference to the pharmaceutical firm’s European initiatives to introduce viable, new products into commerce. He went on to elaborate on the “excitement” of upgrading EUSA already extensive commercial product portfolio. Mostly, the pharmaceutical firm develops anti-cancer medications, based on clinical research.
Carsten Thiel’s: Facebook Page.